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Abstract
Background
Understanding the patterns of HCV RNA levels during acute hepatitis C virus (HCV) infec-
tion provides insights into immunopathogenesis and is important for vaccine design. This
study evaluated patterns of HCV RNA levels and associated factors among individuals with
acute infection.
Methods
Data were from an international collaboration of nine prospective cohorts of acute HCV
(InC3 Study). Participants with well-characterized acute HCV infection (detected within
three months post-infection and interval between the peak and subsequent HCV RNA
levels120 days) were categorised by a priori-defined patterns of HCV RNA levels: i) spon-
taneous clearance, ii) partial viral control with persistence (1 log IU/mL decline in HCV
RNA levels following peak) and iii) viral plateau with persistence (increase or<1 log IU/mL
decline in HCV RNA levels following peak). Factors associated with HCV RNA patterns
were assessed using multinomial logistic regression.
Results
Among 643 individuals with acute HCV, 162 with well-characterized acute HCV were identi-
fied: spontaneous clearance (32%), partial viral control with persistence (27%), and viral
plateau with persistence (41%). HCV RNA levels reached a high viraemic phase within two
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months following infection, with higher levels in the spontaneous clearance and partial viral
control groups, compared to the viral plateau group (median: 6.0, 6.2, 5.3 log IU/mL, respec-
tively; P=0.018). In the two groups with persistence, Interferon lambda 3 (IFNL3) CC geno-
type was independently associated with partial viral control compared to viral plateau
(adjusted odds ratio [AOR]: 2.75; 95%CI: 1.08, 7.02). In the two groups with viral control, fe-
male sex was independently associated with spontaneous clearance compared to partial
viral control (AOR: 2.86; 95%CI: 1.04, 7.83).
Conclusions
Among individuals with acute HCV, a spectrum of HCV RNA patterns is evident. IFNL3 CC
genotype is associated with initial viral control, while female sex is associated with ultimate
spontaneous clearance.
Introduction
Initial infection with hepatitis C virus (HCV) is characterized by detection of virus in blood
within 2–14 days of exposure, increases in hepatic transaminases, and appearance of detectable
HCV-specific antibodies (anti-HCV) within 30–60 days of exposure [1–6]. Understanding of
early HCV RNA patterns during acute HCV infection provides insights into immunopatho-
genesis and is important for vaccine design. However, data in this area remains limited due to
the generally asymptomatic nature of initial infection, the highly marginalised nature of at-risk
populations, such as people who inject drugs (PWID), and small study populations.
Based on available data, the dynamics of HCV RNA levels following HCV exposure indicate
an initial “pre-ramp-up” phase with intermittent low-level viraemia (from exposure to initial
quantifiable HCV RNA), followed by a “ramp-up” phase with an exponential increase in HCV
RNA levels (8–10 days), and a high viraemic plateau phase (45–68 days)[2]. Among the ~25%
with subsequent spontaneous clearance [7, 8], this plateau phase is followed by a decline in
HCV RNA to undetectable levels [9–12]. Among those who subsequently develop persistent
HCV infection, patterns of HCV RNA levels are heterogeneous [3, 12–15], but there are limited
studies investigated the differential patterns of HCV RNA levels in these individuals. A study
of acute HCV infection among HIV co-infected men who have sex with men characterised
those who developed persistent infection into two broad patterns: 1) fluctuating levels of HCV
RNA (1 log IU/mL) corresponding to partial viral control with subsequent persistence; or 2)
stable high HCV RNA levels [11, 16].
Factors associated with spontaneous HCV clearance have been well-described and include
host (e.g. female sex, Interferon lambda 3 [IFNL3] genotype [formerly called IL28B], immune
responses) [7, 8, 15, 17–21] and viral factors (e.g. HCV genotype and viral evolution) [8, 11,
22–25]. However, little is known about the host and viral factors associated with partial viral
control with persistence when compared to either those who achieve spontaneous HCV clear-
ance or those without partial viral control (high viral plateau with persistence).
The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts
(InC3) Study, is a collaborative of pooled data from nine prospective cohorts mainly following
PWID [26], consisting of well-characterized participants with acute HCV infection. This cur-
rent study assessed the dynamics of HCV RNA and alanine aminotransferase (ALT) levels in
acute HCV infection among those with spontaneous clearance and persistent infection.
HCV RNA Patterns during Acute HCV Infection
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Individuals with persistent infection were further categorized into those with high viral plateau
with persistence and partial viral control with persistence.
Materials & Methods
Study population and design
The InC3 Study is a collaboration of nine prospective cohorts evaluating HIV and HCV infec-
tion outcomes [26] All cohorts follow participants at regular intervals using standardized
methods, although participants were recruited and followed over different time periods, be-
tween 1985 and 2010. The InC3 Study includes both: 1) participants without HCV infection;
and 2) participants with acute HCV infection. All participants provided written informed con-
sent and the cohort protocols conform to the ethical guidelines of the 1975 Declaration of Hel-
sinki as reflected in a priori approval by the University of California at San Francisco (UCSF)
Institutional Review Board. The cohort protocols were also approved by local ethics commit-
tees in each site [26].
For the current study, only individuals with acute HCV were included. Acute HCV was de-
fined as either: 1) HCV seroconversion with an anti-HCV negative test followed by either an
anti-HCV or HCV RNA positive test within two years of the anti-HCV negative test; or 2) evi-
dence of symptomatic HCV infection. Symptomatic HCV infection was defined as a) a positive
anti-HCV/HCV RNA test; b) jaundice or ALT elevation>400 U/L; and c) detection of HCV
RNA or history of high-risk exposure within three months of clinical manifestation of acute
HCV.
The estimated date of HCV infection was calculated based on a hierarchy using all serologi-
cal (anti-HCV), virological (HCV RNA) and clinical (symptoms and liver function tests) data
to arrive at the most precise estimate of infection date:
a. Among individuals with HCV RNA positive and anti-HCV negative at acute HCV detec-
tion, date of infection was four weeks prior to HCV RNA detection [3, 6].
b. Among individuals with symptomatic acute HCV, date of infection was six weeks prior to
its onset (jaundice or ALT>400 IU/L) [27].
c. Among individuals with a negative anti-HCV test followed by either a positive anti-HCV or
HCV RNA test, seroconversion was assumed to occur at the mid-point between the last neg-
ative and the first positive test. HCV seroconversion generally occurs about 30–60 days fol-
lowing infection [3, 6, 28]. Date of infection in this group was six weeks prior to estimated
seroconversion date if the first positive test was anti-HCV test and four weeks prior to esti-
mated seroconversion date if the first positive test was only HCV RNA test.
Profiles of levels of HCV RNA and ALT in those with spontaneous clearance and persistent
infection were assessed in 643 (79%) of the 812 persons with acute HCV infection in the InC3
study (Fig. 1). Of the 812, 143 (18%), individuals with unknown virological outcome were ex-
cluded. Individuals treated for HCV within 26 weeks of estimated duration of infection were
also excluded (n = 37; 5%) to reduce misclassification bias resulting from uncertainty around
subsequent spontaneous clearance in the absence of treatment [8, 21].
Among untreated individuals, all longitudinal HCV RNA and ALT measurements were
used to assess the profiles of HCV RNA and ALT levels. Among treated individuals (treatment
commencement after 26 weeks following infection), only HCV RNA and ALT data up to and
including the date of treatment commencement were included in the analysis. Individuals with
documented re-infection episodes after spontaneous clearance were censored at the last unde-
tectable HCV RNA before re-infection [29].
HCV RNA Patterns during Acute HCV Infection
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Patterns of HCV RNA levels were then evaluated in a sub-group of people classified as
“well-characterized acute HCV infection” (Fig. 1). First, the study population was restricted to
individuals with HCV RNA detected within the first three months following estimated date of
infection (n = 210). This reduced the likelihood that changes in early HCV RNA levels would
be missed due to late detection of initial HCV RNA. Two hundred and ten participants met
this criteria including 52 with spontaneous clearance and 158 with persistent infection. Second,
for participants with persistent infection to be classified as having “well-characterized acute
HCV infection” a second HCV RNA test within four months (120 days) of their peak HCV
RNA test was also required. This reduced the likelihood of missing unobserved HCV RNA val-
ues among individuals with persistent infection and wide intervals between consecutive HCV
RNA tests. One hundred and ten participants with persistent infection met this criteria. As
such, 162 paticipants were classified as “well-characterized acute HCV infection” (Fig. 1).
Study outcomes
Spontaneous clearance was defined by two consecutive undetectable HCV RNA test results4
weeks apart following the estimated date of infection [8]. Individuals with persistent infection
Fig 1. Overview of InC3 study population.
doi:10.1371/journal.pone.0122232.g001
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were categorized into two broad a priori-defined groups. Partial viral control with persistence
was defined by a1 log IU/mL decline between the peak HCV RNA level during the first 90
days following infection and the subsequent HCV RNA level (within 120 days from peak).
This group represented individuals who had an initial1 log IU/mL decline in HCV RNA
level and stayed at low levels, or had an initial1 log IU/mL decline in HCV RNA levels and
had a re-increase (fluctuation) during follow-up (for representative examples, see S1 Fig. [A, B,
C]). High viral plateau with persistence (hereinafter called viral plateau with persistence) was
defined by an increase or<1 log IU/mL decline between the peak HCV RNA level during the
first 90 days following infection and the subsequent HCV RNA level (within 120 days from
peak). This group represented individuals who had an increase in HCV RNA level after the
first 90 days following infection, or had relatively stable high HCV RNA levels with<log IU/
mL initial decline (for representative examples, see S1 Fig. [D, E, F]). For participants with
more than one HCV RNA level within 120 days after the peak level,both individual values and
medians were assessed. As results were similar, results with median values are presented.
Among individuals with any of the above described patterns of HCV RNA levels, those with
undetectable HCV RNA followed by detectable HCV RNA during twelve-month follow-up
were classified as having intermittent viraemia. Among those with intermittent viraemia, viral
genotype/subtype data and viral sequence analysis were used to distinguish three subcategories:
reinfection (heterologous virus with no subsequent detection of the original viral strain), inter-
calation (homologous virus), and indeterminate (viral sequencing unavailable, or heterologous
virus with subsequent detection of the original viral strain) [29].
Laboratory testing
Choice of qualitative and quantitative HCV RNA testing varied by cohort but was consistent at
each site. Qualitative HCV RNA testing was performed using the following assays: Versant
TMA [Bayer, Australia;<10 IU/ml], COBAS AmpliPrep/COBAS TaqMan (Roche, Branch-
burg, NJ, USA;<15 IU/ml), COBAS AMPLICOR HCV Test v2.0 (Roche Diagnostics, Mann-
heim, Germany;<50 IU/ml) or discriminatory HCV transcription-mediated amplification
component of the Procleix HIV-1/HCV (Gen-Probe, San Diego, CA, USA;<12 copies/mL).
Quantitative HCV RNA testing was performed using the Versant HCV RNA 3.0 (Bayer,
Australia;<615 IU/ml), COBAS AMPLICOR HCVMONITOR 2.0 (Roche Diagnostics, Mann-
heim, Germany;<600 IU/ml), COBAS AmpliPrep/COBAS TaqMan (Roche, Branchburg, NJ,
USA;<15 IU/ml) or an in-house PCR (<1000 IU/ml) [30, 31]. HCV genotype was determined
by line-probe assay (Versant LiPa1/LiPa2, Bayer, Australia) or HCV sequencing at acute HCV
detection. Among those with undetectable HCV RNA (no genotype) and available samples,
Murex HCV serotyping was performed to determine HCV genotype (Murex Biotech Limited,
Dartford, UK). IFNL3 genotyping was determined by sequencing of the rs12979860 single nu-
cleotide polymorphism, as previously described [8, 18, 19, 21].
Statistical analyses
Population-average curves describing HCV RNA and ALT profiles were constructed using lon-
gitudinal HCV RNA and ALT measurements. The median HCV RNA levels (log IU/mL) and
ALT levels (IU/L) among all individuals (n = 643) were calculated in monthly intervals for the
first 12 months following estimated date of infection. To calculate monthly medians of HCV
RNA and ALT levels, all individual measurements recorded during each month were included.
Medians of HCV RNA and ALT levels were compared between groups using Wilcoxon-Mann-
Whitney test or Kruskal Wallis test. Similar analyses were performed in those with well-
characterized acute HCV infection (n = 162).
HCV RNA Patterns during Acute HCV Infection
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To account for within-individual clustering of data points (repeated measurements) and the
natural heterogeneity of the population a random effects linear regression model was fitted for
the different patterns of HCV RNA levels. Overall time trends were allowed to vary smoothly
using natural cubic splines [32]. The intercept and the slope were allowed to differ per individ-
ual via the random effects.
Factors associated with patterns of HCV RNA levels were assessed among those with well-
characterized acute HCV infection (n = 162). Hypothesized factors were determined a priori
based on factors known to be associated with spontaneous clearance of HCV infection and in-
cluded age [33]. Sex [7, 8, 15, 17, 18], ethnicity [34], IFNL3 genotype (SNP rs12979860; CC vs.
CT/TT) [8, 19–21], HIV co-infection [34], and HCV genotype (genotype 1 vs. genotype non-
1) [8, 11, 22]. Due to the data of higher spontaneous clearance in HCV genotype 1 [8, 11, 22],
and the small numbers within some genotype categories (2/4/6/mixed), all HCV genotype
non-1 infections were grouped together.
first, the distribution of each hypothesised factor was compared between those with sponta-
neous clearance, partial viral control with persistence and viral plateau with persistence using
chi square for categorical variables and kruskal wallis test for continuous variables. a multino-
mial logistic regression model was used for multivariate analyses, including factors with an
overall P value<0.20 in unadjusted analysesl. two separate models were fitted considering viral
plateau with persistence and partial viral control with persistence as the baselines, respectively.
given that peak hcv rna levels (iu/ml) and log10 transformation (log iu/ml) of these data was
not normally distributed, a dichotomised version of this variable was included in the model
using a threshold of 400,000 iu/ml (5.6 log iu/ml) [35]. statistically significant differences were
assessed at P<0.05; p-values were two-sided. all analyses were performed using stata v12.0 (col-
lege station, tx, united states).
Results
Participant characteristics
The characteristics of the population with acute HCV infection included in this study (n = 643)
are summarized in Table 1. Median age was 26 years, 36% were female, 96% had a history of in-
jecting drug use, and 17% (n = 112) received HCV treatment during follow-up (all treated indi-
viduals included started treatment at>26 weeks following infection). Acute HCV infection
was documented by HCV seroconversion in 89% (n = 573) of participants; 183 of these were
HCV RNA positive and anti-HCV negative at acute HCV detection. During the first 12 months
following estimated date of HCV infection, a median of three HCV RNA tests (inter-quartile
range [IQR]: 2, 5), with a median of 35 days (IQR: 23, 91) between tests, were included. The
median interval from estimated date of infection to the first positive anti-HCV or HCV RNA
test was 101 days (IQR: 28, 172). The overall median follow-up time from the estimated date of
infection to the last HCV RNAmeasurement was 19 months (IQR: 9, 36).
HCV RNA and ALT levels during acute infection, by infection outcome
HCV RNA and ALT levels among those with spontaneous clearance and persistent infection
were assessed among 643 participants with acute HCV infection (173 with spontaneous clear-
ance and 470 with persistent infection; Fig. 2).
Peak median HCV RNA levels occurred at one month following infection in those with
spontaneous clearance (5.7 log IU/mL; IQR: 3.0, 7.0) and at months one and two in those with
persistent infection (month one: 5.4 log IU/mL; IQR: 3.8, 6.5 and month two: 5.4 log IU/m;
IQR: 3.1, 6.4; P = 0.39 for month one comparison). By month two to four, HCV RNA declines
were seen in both groups. At month two, median HCV RNA levels remained comparable
HCV RNA Patterns during Acute HCV Infection
PLOS ONE | DOI:10.1371/journal.pone.0122232 April 2, 2015 6 / 19
Table 1. Characteristics of individuals with acute HCV infection in the InC3 Study.
Number (%)*
Overall (n = 643)
Site
ACS (the Netherlands) 44 (7)
ATAHC (Australia) 125 (19)
BAHSTION (United States) 50 (8)
BBAASH (United States) 114 (17)
HEPCO (Canada) 78 (12)
HITS-c (Australia) 10 (2)
HITS-p (Australia) 90 (14)
N2 (Australia) 17 (3)
UFO (United States) 115 (18)
Median age at the time of HCV infection, yrs (IQR**) 26 (23, 33)
Sex
Female 230 (36)
Male 411 (64)
Unknown 2 (<1)
Ethnicity
Caucasian 525 (82)
Black 24 (4)
Indigenous 32 (5)
Other 47 (7)
Unknown 15 (2)
History of injecting drug use 616 (96)
Documented acute HCV infection by:
HCV seroconversion 573 (89)
Symptomatic infection, and a recent history of high-risk exposure 70 (11)
Clinical illness at the time of acute HCV infection
No 120 (19)
Yes 139 (22)
Unknown 384 (61)
IFNL3 genotype (rs12979860)
TT 64 (10)
CT 215 (33)
CC 272 (42)
Unknown 92 (14)
HIV status at the time of HCV infection
Negative 574 (89)
Positive 44 (7)
Unknown 25 (4)
HCV genotype
Genotype 1 302 (47)
Genotype 2 33 (5)
Genotype 3 187 (29)
Genotype 4 7 (1)
Genotype 6 4 (1)
Mixed genotype 14 (2)
Unknown 96 (15)
* Percentages indicate column percentages;
** IQR: Inter-quartile range
doi:10.1371/journal.pone.0122232.t001
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between individuals with persistent infection (5.4 log IU/mL; IQR: 3.1, 6.4) and spontaneous
clearance (4.8 log/IU/mL; IQR: 0.0, 6.0; P = 0.38). Median HCV RNA levels initially diverged
at three months following infection, being 4.8 log/IU/mL (IQR: 3.3, 6.0) in individuals with
persistent infection compared to 3.2 log/IU/mL (IQR: 0.0, 6.1) in those with spontaneous clear-
ance (P = 0.03). Subsequent marked divergence in median HCV RNA level between the two
groups was seen at month four and beyond (Fig. 2A).
Peak HCV RNA preceded peak ALT by approximately one month, with peak ALT levels
being observed in month two following infection among individuals with persistent infection
(354 IU/L; IQR: 99, 944) and spontaneous clearance (463 IU/L; IQR: 72, 2316; P = 0.43). By
month four to five following infection, median ALT level had declined sharply in both groups.
Among individuals with spontaneous clearance, median ALT returned to normal at month
five and remained within the normal range thereafter. In contrast, in those with persistent in-
fection, median ALT levels remained elevated throughout follow-up with intermittent fluctua-
tions (Fig. 2B). Similar results were observed in sensitivity analyses (S2 Fig.) restricted to
individuals identified in the so called sero-silent acute HCV phase (HCV RNA positive and
anti-HCV negative) given the well-defined estimated date of infection in this sub-group
(n = 183).
Patterns of HCV RNA levels among individuals with well-characterized
acute HCV infection
To further characterise the different patterns of HCV RNA levels, longitudinal HCV RNA lev-
els were assessed among individuals with well-characterized acute HCV infection (n = 162).
Compared to those not included in this analysis (n = 481), included individuals were younger,
were less likely to be Caucasians, and more likely to have sympotomatic acute infection (S1
Table).
Individuals with well-characterized acute HCV infection (n = 162) had a median of 4.5
HCV RNA tests (IQR: 3, 8), with a median of 33 days (IQR: 27, 68) between tests during the
first 12 months following estimated date of HCV infection. Median interval from estimated
date of infection to the first positive anti-HCV or HCV RNA test was 28 days (IQR: 28, 49).
Spontaneous clearance was observed in 52 individuals. Among those with persistent infection
(n = 110), 44 individuals demonstrated partial viral control with persistence (defined by1 log
IU/mL decline between the peak and the subsequent HCV RNA levels) and 66 individuals
demonstrated viral plateau with persistence (defined by increase or<1 log IU/mL decline be-
tween the peak and the subsequent HCV RNA levels). HCV RNA levels among individuals
with these three HCV RNA patterns are illustrated in Fig. 3.
Among 66 individuals with viral plateau and persistence, consistently high HCV RNA levels
with irregular fluctuations were observed throughout follow-up. Representative examples of
HCV RNA levels among individual cases are shown in S1 Fig. (D, E, F). Intermittent viraemia
was observed in four participants in this group during twelve-months of follow-up, including
one case of intercalation, three indeterminate cases, and no re-infections.
Among 44 individuals with partial viral control and persistence, HCV RNA levels declined
after the peak and rebounded following months 4–5. Representative examples of HCV RNA
levels among individual cases are shown in S1 Figs. (A, B, C). The decline in median HCV
RNA levels between month two and five was 3.7 log IU/mL. HCV RNA levels observed after
viral rebound were lower than the initial values. The patterns of HCV RNA levels were relative-
ly similar between individuals with partial control and those with viral plateau after months
8–10 following infection. Intermittent viraemia was observed in 10 participants with partial
HCV RNA Patterns during Acute HCV Infection
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Fig 2. Monthly medians of HCV RNA and ALT levels in individuals with acute HCV infection in the InC3
study (total n = 643). (A) HCV RNA levels, by infection outcome (clearance vs. persistence); (B) ALT levels
by infection outcome (clearance vs. persistence), tables underneath panel A and B represent number of
participants with available HCV RNA/ALT levels measurements at each time point; (C) Fitted HCV RNA
patterns, shaded areas in panel C represent the 95% confidence intervals.
doi:10.1371/journal.pone.0122232.g002
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Fig 3. Patterns of HCV RNA levels in individuals with well-characterized acute HCV infection in the
InC3 study (total n = 162). (A) Monthly medians of HCV RNA levels, table underneath represents number of
participants with available HCV RNA level measurements at each time point; (B) Fitted HCV RNA patterns,
shaded areas represent the 95% confidence intervals.
doi:10.1371/journal.pone.0122232.g003
HCV RNA Patterns during Acute HCV Infection
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control and persistence during twelve months of follow-up, including six cases of intercalation,
four indeterminate cases, and no re-infections.
Median (IQR) HCV RNA levels at month one following infection were 6.0 log IU/mL (4.3,
7.1), 6.2 log IU/mL (5.2, 7.1), and 5.3 log IU/mL (4.1, 6.0) in individuals with spontaneous
clearance, partial viral control with persistence, and viral plateau with persistence, respectively
(P = 0.02). Compared to those with viral plateau with persistence, median HCV RNA levels
was significantly higher in participants with spontaneous clearance (P = 0.03) and partial viral
control with persistence (P<0.01). However, median HCV RNA levels did not significantly dif-
fer between participants with partial viral control compared to those with clearance (P = 0.68).
Factors associated with patterns of HCV RNA levels
Among individuals with well-characterized acute HCV, key baseline characteristics were com-
pared among those with viral plateau with persistence (n = 66), partial viral control with persis-
tence (n = 44) and spontaneous clearance (n = 52; Table 2, Fig. 4). Between the three groups,
there was a significant difference in the proportion with IFNL3 CC genotype (29% vs. 51% vs.
63%, respectively; P<0.01), median peak HCV RNA level (5.3 log IU/mL vs. 6.0 log IU/mL vs.
6.5 log IU/mL, respectively; P<0.01) and the proportion with peak HCV RNA5.6 log IU/mL
(39% vs. 61% vs. 67%, respectively; P<0.01). There was also a trend towards a significant differ-
ence in sex across the three groups, with 54% of individuals with spontaneous HCV clearance
being female, as compared to 37% in those with partial viral control with persistence and 35%
in those with viral plateau with persistence (P = 0.09).
As female sex may have a role in modifying the association of IFNL3 genotype with HCV
viral control [8, 18], the proportion of IFNL3 CC genotype was assessed stratified by sex. As
shown in Fig. 4E, the difference in the proportion of IFNL3 CC genotype was more pro-
nounced among females compared to males when comparing those with partial viral control
with persistence and spontaneous clearance.
Table 3 presents multinomial logistic regression models of factors associated with viral pla-
teau with persistence, partial viral control with persistence and spontaneous clearance. IFNL3
genotype, sex, HCV genotype and peak HCV RNA levels, were included in subsequent models,
given the associations observed in unadjusted analyses (P<0.20). In the two groups with viral
persistence, the only factor independently associated with partial viral control (compared to
viral plateau) was IFNL3 CC genotype (adjusted odds ratio [AOR]: 2.75; 95% CI: 1.08, 7.02;
P = 0.03). In the two groups with viral control, the only factor independently associated with
spontaneous clearance (compared to partial viral control with persistence) was female sex
(AOR: 2.86; 95% CI: 1.04, 7.83; P = 0.04). Lastly, female sex (AOR: 3.10; 95% CI: 1.18, 8.17;
P = 0.02), IFNL3 CC genotype (AOR: 5.00; 95% CI: 1.85, 13.51; P<0.01), HCV genotype 1
(AOR: 3.50; 95% CI: 1.24, 9.87; P = 0.02), and peak HCV RNA level5.6 log IU/mL (AOR:
3.77; 95% CI: 1.38, 10.28; P = 0.01) were all independently associated with spontaneous clear-
ance compared to viral plateau with persistence.
Discussion
This study has characterized the patterns of HCV RNA and ALT levels in a large population
with well-defined acute HCV infection, the majority of whom were PWID. Following acute
HCV infection, HCV RNA levels reached a high viraemic phase followed by either spontane-
ous clearance or persistent infection, with the divergence of HCV RNA levels occurring at ap-
proximately three months following infection. Two broad patterns of HCV RNA levels were
designated a priori among individuals with persistent infection in this study, including viral
plateau with persistence and partial viral control with persistence. IFNL3 CC genotype and
HCV RNA Patterns during Acute HCV Infection
PLOS ONE | DOI:10.1371/journal.pone.0122232 April 2, 2015 11 / 19
female sex emerged as the most predictive factors for viraemia patterns. Among individuals
who develop viral persistence (viral plateau and partial viral control), IFNL3 CC genotype ap-
pears to be the most predictive factor of initial viral control. Furthermore, among those who ex-
hibit some degree of viral control (clearance or partial viral control with persistence), female
sex is particularly important for determining whether someone will ultimately spontaneously
clear the infection.
Differential patterns of HCV RNA levels may reflect a spectrum of immunological viral con-
trol during acute infection. Partial viral control with persistence is indicative of a complex pat-
tern of virus–host interaction and can represent loss of immunological control of viral
Table 2. Distribution of selected demographic, clinical and virologic variables by various patterns of HCV RNA levels in individuals with well-char-
acterized acute HCV infection in the InC3 study (n = 162).
Viral plateau with
persistence (n = 66)
n (%)*
Partial viral control
with persistence
(n = 44) n (%)*
Spontaneous
clearance (n = 52)
n (%)*
P (across
three
groups)
P (Viral plateau
vs. Partial viral
control)
Median age, yrs (IQR**) 24 (21, 28) 24 (22, 30) 24 (21, 28) 0.66 0.54
Sex 0.09 0.80
Male 43 (65) 27 (63) 24 (46)
Female 23 (35) 16 (37) 28 (54)
Ethnicity 0.65 0.89
Caucasian 49 (78) 35 (81) 44 (85)
Black 7 (11) 3 (7) 1 (2)
Indigenous 2 (3) 1 (2) 1 (2)
Other 5 (8) 4 (9) 6 (11)
IFNL3 genotype (rs12979860) <0.01 0.03
TT/CT 42 (71) 17 (49) 18 (37)
CC 17 (29) 18 (51) 31 (63)
HIV status 0.68 0.65
Negative 61 (95) 42 (98) 48 (98)
Positive 3 (5) 1 (2) 1 (2)
HCV genotype 0.18 0.32
Genotype non-1 29 (45) 13 (35) 11 (27)
Genotype 1 35 (55) 24 (65) 29 (72)
Median peak HCV RNA levels
during three months following
infection, log IU/mL (IQR**)
5.3 (3.6–6.0) 6.0 (5.1–7.2) 6.5 (5.3–7.2) <0.01 <0.01
Peak HCV RNA levels during three
months following infection, log IU/
mL
<0.01 0.02
<5.6 log IU/mL 40 (61) 17 (39) 17 (33)
5.6 log IU/mL 26 (39) 27 (61) 35 (67)
Presentation of acute HCV infection 0.35 0.24
Simultaneous HCV RNA+ and anti-
HCV-
40 (61) 33 (75) 37 (71)
Asymptomatic seroconversion† 18 (27) 9 (20) 12 (23)
Symptomatic acute HCV‡ 8 (12) 2 (5) 3 (6)
* Percentages indicate column percentages
** IQR: Inter-quartile range
† A negative anti-HCV test followed by a positive anti-HCV/HCV RNA test
‡ A positive anti-HCV/HCV RNA test and jaundice or ALT elevation >400 U/L
doi:10.1371/journal.pone.0122232.t002
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Fig 4. Distribution of sex, HCV genotype, IFNL3 genotype and peak HCV RNA levels by patterns of HCV RNA levels in individuals with acute HCV
infection in the InC3 study. (A) Sex, P = 0.09; (B) HCV genotype, P = 0.18; (C) IFNL3 genotype, P<0.01; (D) Peak HCV RNA levels, P<0.01; (E) IFNL3
genotype stratified by sex, male P = 0.03, female P = 0.02.
doi:10.1371/journal.pone.0122232.g004
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replication due to virological escape from initial innate responses or a failure in the kinetics,
magnitude or breadth of HCV-specific adaptive immune responses (reviewed in [16, 36]).
Rapid viral evolution occurs during acute HCV infection, with a higher genetic diversity ob-
served among those with ultimate persistence as compared to clearance [11, 25]. Reductions in
HCV RNA levels and genetic diversity have been identified within 100 days of infection (a
“bottleneck” effect) irrespective of infection outcome, with subsequent increased HCV RNA
levels and diversity in those with persistent infection [37]. The pattern of HCV RNA levels in
those with partial viral control and persistence obsereved in the current study is consistent
with these data, given this control was observed largely between months 3–5 (90–150 days).
Vigorous but late onset HCV-specific T-cell responses have been also identified in individuals
with transient viral control in acute HCV infection, while ultimately loss of HCV-specific T-
cell responses has led to recurrent HCV viraemia and persistent infection (reviewed in [36,
38]). Although two broad patterns of HCV RNA levels were defined among individuals with
persistent infection in this study, heterogeneity in individual HCV RNA patterns is still evident
in these two groups [3, 12–15].
Among individuals with well-characterized acute HCV infection who eventually developed
viral persistence, a notable proportion (40%) initially experienced at least one log IU/mL de-
cline in their HCV RNA levels. This finding has clinical implications suggesting that spontane-
ous clearance cannot be predicted solely based on initial decline in HCV RNA levels.
Among individuals with persistent infection, IFNL3 CC genotype was independently associ-
ated with partial viral control (either a decrease or fluctuation in HCV RNA). Previous studies
have demonstrated that genetic variation in the IFNL3 gene region is associated with both
spontaneous and treatment-induced HCV clearance (reviewed in [4, 23]). Our findings suggest
that even among individuals who develop persistent infection, IFNL3 CC genotype plays a role
Table 3. Adjustedmultinomial logistic regression model assessing factors associated with patterns of HCV RNA levels in individuals with well-
characterized acute HCV infection in the InC3 study*.
Partial viral control with persistence
vs. Viral plateau with persistence**
AOR† (95% CI)
P Spontaneous clearance vs. Partial
viral control with persistence**
AOR† (95% CI)
P Spontaneous clearance vs. Viral
plateau with persistence**
AOR† (95% CI)
P
Sex
Male 1.00 1.00 1.00
Female 1.08 (0.42, 2.82) 0.87 2.86 (1.04, 7.83) 0.04 3.10 (1.18, 8.17) 0.02
IFNL3 genotype (rs12979860)
TT/CT 1.00 1.00 1.00
CC 2.75 (1.08, 7.02) 0.03 1.82 (0.64, 5.12) 0.26 5.00 (1.85, 13.51) <0.01
HCV genotype
Genotype
non-1
1.00 1.00 1.00
Genotype
1
1.65 (0.65, 4.20) 0.29 2.11 (0.72, 6.21) 0.17 3.50 (1.24, 9.87) 0.02
Peak HCV RNA levels
<5.6 log
IU/mL
1.00 1.00 1.00
5.6 log
IU/mL
2.15 (0.85, 5.41) 0.10 1.75 (0.59, 5.18) 0.31 3.77 (1.38, 10.28) 0.01
*Included 128 participants in the model
**Baseline comparison group
† AOR: Adjusted Odds Ratio
doi:10.1371/journal.pone.0122232.t003
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in initial viral control. Some other studies also demonstrated an association between IFNL3 CC
genotype and higher HCV RNA levels in acute infection, regardless of acute HCV outcome
[10, 39], and also in chronic infection [40–42]. Although the mechanisms and role of IFNL3 ge-
notype in viral control and outcome of HCV infection are not fully understood, there is evi-
dence that IFNL3 regulates the interferon stimulated genes (ISGs), required for initial control
of viral infection (reviewed in[43]). Another study demonstrated a superior innate immune
function, particularly of natural killer cells, to interferon-based therapy in individuals with
IFNL3 CC genotype, resulting in improved treatment induced viral control [44]. More evi-
dence is needed to show if there is the same association between IFNL3 genotype and natural
killer cells function in acute HCV infection although the existing evidence supports the essen-
tial role of natural killer cells in viral control in acute HCV through inducing T-cell responses
(reviewed in [45]).
Among individuals with viral control, female sex was independently associated with sponta-
neous clearance, consistent with the increasing literature demonstrating that females exhibit
more successful responses to HCV [7, 8, 15, 17, 18]. However, it is interesting that among
those with any level of viral control (partial control or clearance), female sex is particularly im-
portant for determining HCV clearance outcome. Unfortunately, data on sex-based differences
in immunological profiles in individuals with HCV infection are sparse. However, there is evi-
dence of a lower rate of HCV clearance in men compared to women [7, 8, 15, 17, 18] and also
in postmenopausal women compared to premenopausal women [46, 47] implicating female
hormones, such as estrogens and progesterone, in viral control.
Female sex, IFNL3 CC genotype, HCV genotype 1, and higher peak HCV RNA levels were
significantly associated with spontaneous clearance when compared to participants with viral
plateau and persistence. These findings are consistent with previous data demonstrating the as-
sociation of female sex [7, 8, 15, 17, 18], IFNL3 CC genotype [8, 19–21], HCV genotype 1 [8,
11, 22] and peak HCV RNA levels [10] with spontaneous HCV clearance following
acute infection.
The current study did not show any significant association between age and the patterns of
HCV RNA levels, although previous studies identified higher spontaneous clearance rate in
younger individuals [33]. InC3 participants are generally young, given HCV transmission
among PWID generally occurs in young age. However, this study may not able to explore the
potential association of age with HCV RNA patterns due to a narrow age range.
While the current study is unique given the large sample size and well-defined nature of
acute HCV infection, there are several limitations. Participating cohorts bring a range of data
types and structures presenting issues surrounding both inconsistent measurement and biolog-
ical data testing protocols (e.g. HCV RNA assays differed across cohorts with different sensitiv-
ity, specificity and lower limit of detection). It is important to note that the definition of partial
viral control in this study included either a decrease or fluctuation in HCV RNA, so the HCV
RNA curves for partial controllers represent the average curve. There was also heterogeneity in
HCV RNA and ALT monitoring schedules across cohorts. We were not able to explore the po-
tential association of individual genotypes with HCV RNA patterns, due to the relatively small
numbers of some HCV genotypes. Individuals with well-characterised acute HCV infection
were not representative of entire InC3 participants given significant difference in distribution
of some background characteristics between this group and the rest of InC3 participants (e.g.
age, ethnicity, and sympotomatic acute infection).
In conclusion, this study identified factors associated with three broad patterns of HCV
RNA levels during acute HCV infection. These findings have important implications for un-
derstanding the immunological and genetic features important for the control of HCV infec-
tion, and have implications for HCV vaccine research. Further research is required to better
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understand the mechanisms behind the association of IFNL3 genotype on early viral control
and the mechanisms explaining the sex-based immune response to HCV infection.
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